Clinical • Trial completion • Trial completion date • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha)
|
HER-2 amplification • PIK3CA mutation
|
Herceptin (trastuzumab) • Piqray (alpelisib) • elgemtumab (LJM-716)